Jefferies Group LLC Abb Vie Inc. Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

A detailed history of Jefferies Group LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Jefferies Group LLC holds 70,155 shares of ABBV stock, worth $16.4 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

70,155

Previous 53,162 31.96%

Holding current value

$16.4 Million

Previous $8.14 Million 15.63%

% of portfolio

0.09%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Sep 21, 2023	BUY	$134.21 - $153.93 $2.28 Million - $2.62 Million	16,993 Added 31.96%	70,155 $9.42 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $2.75 Million - $3.15 Million	20,467 Added 38.5%	73,629 $9.39 Million
Q2 2022 Sep 21, 2023	BUY	$137.62 - $174.96 $933,889 - $1.19 Million	6,786 Added 14.63%	53,162 $8.14 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $933,889 - $1.19 Million	6,786 Added 14.63%	53,162 $8.14 Million
Q1 2022 Sep 21, 2023	BUY	$131.98 - $163.75 $2.66 Million - $3.31 Million	20,186 Added 77.08%	46,376 $7.52 Million

Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $2.66 Million - $3.31 Million	20,186 Added 77.08%	46,376 $7.52 Million
Q4 2021 Sep 21, 2023	BUY	$107.43 - $135.93 $698,724 - $884,088	6,504 Added 33.04%	26,190 $3.55 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $698,724 - $884,088	6,504 Added 33.04%	26,190 $3.55 Million
Q3 2021 Sep 21, 2023	BUY	$106.4 - $120.78 $1.89 Million - $2.14 Million	17,717 Added 899.8%	19,686 $2.12 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.89 Million - $2.14 Million	17,717 Added 899.8%	19,686 $2.12 Million
Q2 2021 Sep 21, 2023	BUY	$105.21 - $117.21 $32,404 - $36,100	308 Added 18.54%	1,969 $221,000
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $207,158 - $230,786	1,969 New	1,969 $222,000
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $169,920 - $187,061	-1,661 Closed	0 $0
Q4 2020 Sep 21, 2023	SELL	$80.49 - $108.67 $5.79 Million - $7.82 Million	-71,968 Reduced 97.74%	1,661 $177,000
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $70,589 - $95,303	-877 Reduced 34.55%	1,661 $178,000
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $1.21 Million - $1.42 Million	-14,085 Reduced 84.73%	2,538 $222,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $8.3 Million - $11.1 Million	-113,091 Reduced 87.18%	16,623 $1.63 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $5.82 Million - $8.82 Million	90,196 Added 228.24%	129,714 $9.88 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $1.76 Million - $2.2 Million	24,382 Added 161.09%	39,518 $3.5 Million
Q3 2019 Nov 13, 2019	SELL	$62.98 - $75.72 $2.99 Million - $3.6 Million	-47,501 Reduced 75.84%	15,136 $1.15 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $1.51 Million - $1.92 Million	22,922 Added 57.72%	62,637 $4.56 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $2.25 Million - $2.65 Million	29,155 Added 276.09%	39,715 $3.2 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $4.9 Million - $6.05 Million	-62,993 Reduced 85.64%	10,560 $974,000
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $10.8 Million - $12 Million	-121,678 Reduced 62.33%	73,553 $6.96 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $4.36 Million - $5.16 Million	48,564 Added 33.11%	195,231 $18.1 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $8.18 Million - $11 Million	88,878 Added 153.8%	146,667 $13.9 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $2.73 Million - $2.99 Million	-30,451 Reduced 34.51%	57,789 $5.59 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $6.16 Million - $7.87 Million	88,240	88,240 $7.84 Million

Others Institutions Holding ABBV

# of Institutions

4,485

Shares Held

1.28B

Call Options Held

17.1M

Put Options Held

15.4M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $414B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account

Jefferies Group LLC Abb Vie Inc. Transaction History